May 10, 2017 / 11:45 AM / 6 months ago

EpiPen maker Mylan's profit surges

May 10 (Reuters) - EpiPen maker Mylan NV said on Wednesday first-quarter profit more than quadrupled, as the maker of generic drugs benefited from strong demand outside the United States.

The company said net income rose to $66.4 million, or 12 cents per share in the first quarter ended March 31, from $13.9 million, or 3 cents per share, a year earlier.

Revenue rose to $2.69 billion from $2.18 billion.

Mylan has been heavily criticized over steep price increases for EpiPen, its life-saving allergy shot, and also for classifying the treatment as a generic rather than a branded product, leading to smaller rebates to state Medicaid programs. (Reporting by Natalie Grover in Bengaluru; Editing by Sai Sachin Ravikumar)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below